Homocysteine as a predictor of cognitive decline in Alzheimer's disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Moderately elevated levels of plasma total homocysteine are associated with an increased risk of developing Alzheimer's disease. We have tested whether baseline concentrations of homocysteine relate to the subsequent rate of cognitive decline in patients with established Alzheimer's disease (AD). Methods: In 97 patients with AD, 73 pathologically‐confirmed, we analysed the decline of global cognitive test scores (CAMCOG) over time from the first assessment for at least three 6‐monthly visits up to a maximum of 9.5 years (in total 689 assessments). Non‐linear mixed‐effects statistical models were used. Results: Baseline homocysteine levels showed a concentration‐response relationship with the subsequent rate of decline in CAMCOG scores: the higher the homocysteine, the faster the decline. The relationship was significant in patients aged < 75 years who had not suffered a prior stroke. For example, in patients aged 65 years with a baseline homocysteine of 14 µmol/L, the decline from a CAMCOG score of 88 to a score of 44 occurred 19.2 (95% CI 6.8, 31.6) months earlier than in patients with a baseline homocysteine of 10 µmol/L. Conclusions: Raised homocysteine concentrations within the normal range among the elderly strongly relate to the rate of global cognitive decline in patients with Alzheimer disease. Plasma homocysteine can readily be lowered by B‐vitamin treatment and trials should be carried out to see if such treatments can slow the rate of cognitive decline in relatively young patients with Alzheimer disease. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mixed-Effects Models in Sand S-PLUS
Pinheiro, J. C., & Bates, D. M. (2000) · Statistics and Computing · doi:10.1007/978-1-4419-0318-1 · Cited by 11,187
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590 · cited 2×
“…decline is surprising in relation to the additive effect of vascular disease and AD pathology found in other studies (Esiri et al., 1999; Nagy et al., 1997; Snowdon et al., 1997) and contrasts with the increased rate of decline found after incident stroke in patients with AD (Regan et al., 2006).”
ResultMixed-Effects Models in S and S-PLUS
(2000) · Statistics and Computing · doi:10.1007/b98882 · Cited by 930
Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease
Esiri, M. M., Nagy, Z., Smith, M. Z., Barnetson, L., & Smith, A. D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02355-7 · Cited by 493
Self-citationJacobs, D., Sano, M., Marder, K., Bell, K., Bylsma, F., Lafleche, G., Albert, M., Brandt, J., & Stern, Y. (1994) · Neurology · doi:10.1212/wnl.44.7.1215 · Cited by 266
Low vitamin B-12 status and risk of cognitive decline in older adults
Clarke, R., Birks, J., Nexo, E., Ueland, P. M., Schneede, J., Scott, J., Molloy, A., & Evans, J. G. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1384 · Cited by 203
Cited by
Homocysteine, B Vitamins, and Cognitive Impairment
Smith, A. D., & Refsum, H. (2016) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071715-050947 · Cited by 513
Self-citationLong-term PM 2.5 Exposure and Neurological HospitalAdmissions in the Northeastern United States
Kioumourtzoglou, M.-A., Schwartz, J. D., Weisskopf, M. G., Melly, S. J., Wang, Y., Dominici, F., & Zanobetti, A. (2016) · Environmental Health Perspectives · doi:10.1289/ehp.1408973 · Cited by 466
de Jager, C. A., Oulhaj, A., Jacoby, R., Refsum, H., & Smith, A. D. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2758 · Cited by 457
Self-citationESPEN guidelines on nutrition in dementia
Volkert, D., Chourdakis, M., Faxen-Irving, G., Frühwald, T., Landi, F., Suominen, M. H., Vandewoude, M., Wirth, R., & Schneider, S. M. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.09.004 · Cited by 442
The Molecular and Cellular Effect of Homocysteine Metabolism Imbalance on Human Health
Škovierová, H., Vidomanová, E., Mahmood, S., Sopková, J., Drgová, A., Červeňová, T., Halašová, E., & Lehotský, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101733 · Cited by 422
Homocysteine and Dementia: An International Consensus Statement
Smith, A. D., Refsum, H., Bottiglieri, T., Fenech, M., Hooshmand, B., McCaddon, A., Miller, J. W., Rosenberg, I. H., & Obeid, R. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171042 · Cited by 360
Self-citationTOR‐mediated regulation of metabolism in aging
Antikainen, H., Driscoll, M., Haspel, G., & Dobrowolski, R. (2017) · Aging Cell · doi:10.1111/acel.12689 · Cited by 122
“…with age (Selhub, 1999; Tucker et al., 2005; Smith & Refsum, 2016) and is an independent risk factor for aging-related diseases such as Alzheimer’s disease (Clarke et al., 1998; Oulhaj et al., 2010; Beydoun et al., 2014; Smith & Refsum, 2016) and cardiovascular disease (Refsum et al., 1998).”
BackgroundVitamin B12status, cognitive decline and dementia: a systematic review of prospective cohort studies
O'Leary, F., Allman-Farinelli, M., & Samman, S. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512004175 · Cited by 96
Unified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41
“An elevated homocysteine blood level is a predictor of cognitive decline in AD [323].”
Background
Metadata
- Authors
- Oulhaj, A., Refsum, H., Beaumont, H., Williams, J., King, E., Jacoby, R., & Smith, A. D.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2009-12-15
- Volume
- 25
- Issue
- 1
- Pages
- 82-90
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W1973045469
- Cited by
- 124
- References
- 6
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.